**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 53791

**Manuscript Type:** REVIEW

**Oxidative stress in alcohol-related liver disease**

Tan HK *et al*. Oxidative stress in ALD

Huey K Tan, Euan Yates, Kristen Lilly, Ashwin D Dhanda

**Huey K Tan, Euan Yates, Kristen Lilly, Ashwin D Dhanda**, Hepatology Research Group, Institute of Translational and Stratified Medicine, Faculty of Health, University of Plymouth, Plymouth PL6 8BU, United Kingdom

**Huey K Tan, Ashwin D Dhanda,** South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth PL6 8DH, United Kingdom

**Kristen Lilly,** Department of Clinical Immunology, University Hospitals Plymouth NHS Trust, Plymouth PL6 8DH, United Kingdom

**Author contributions:** Tan HK and Yates E contributed equally to this work; Tan HK, Yates E and Lilly K reviewed and analyzed the literature; all authors contributed to the writing; Dhanda AD finalized the paper.

**Corresponding author:** **Ashwin D Dhanda, BSc, MBChB, MRCP, PhD, Associate Professor,** South West Liver Unit, University Hospitals Plymouth NHS Trust, Derriford Road Crownhill, Plymouth PL6 8DH, United Kingdom. [ashwin.dhanda@plymouth.ac.uk](mailto:ashwin.dhanda@plymouth.ac.uk)

**Received:** December 31, 2019

**Revised:** May 6, 2020

**Accepted:** May 15, 2020

**Published online:**

**Abstract**

Alcohol consumption is one of the leading causes of the global burden of disease and results in high healthcare and economic costs. Heavy alcohol misuse leads to alcohol-related liver disease, which is responsible for a significant proportion of alcohol-attributable deaths globally. Other than reducing alcohol consumption, there are currently no effective treatments for alcohol-related liver disease. Oxidative stress refers to an imbalance in the production and elimination of reactive oxygen species and antioxidants. It plays important roles in several aspects of alcohol-related liver disease pathogenesis. Here, we review how chronic alcohol use results in oxidative stress through increased metabolism *via* the cytochrome P450 2E1 system producing reactive oxygen species, acetaldehyde and protein and DNA adducts. These trigger inflammatory signaling pathways within the liver leading to expression of pro-inflammatory mediators causing hepatocyte apoptosis and necrosis. Reactive oxygen species exposure also results in mitochondrial stress within hepatocytes causing structural and functional dysregulation of mitochondria and upregulating apoptotic signaling. There is also evidence that oxidative stress as well as the direct effect of alcohol influences epigenetic regulation. Increased global histone methylation and acetylation and specific histone acetylation inhibits antioxidant responses and promotes expression of key pro-inflammatory genes. This review highlights aspects of the role of oxidative stress in disease pathogenesis that warrant further study including mitochondrial stress and epigenetic regulation. Improved understanding of these processes may identify novel targets for therapy.

**Key words:** Alcohol-related liver disease; Alcoholic hepatitis; Oxidative stress; Reactive oxygen species; Antioxidants; Epigenetics; Mitochondrial stress

Tan HK, Yates E, Lilly K, Dhanda AD. Oxidative stress in alcohol-related liver disease. *World J Hepatol* 2020; In press

**Core tip:** Alcohol is a global health problem with alcohol-related liver disease forming a significant proportion of alcohol-attributable deaths. However, there are no effective treatments for alcohol-related liver disease. Oxidative stress plays multiple roles in disease pathogenesis, which if better understood may yield new therapeutic targets. Here, we review the current literature on how alcohol consumption leads to oxidative stress and how this results in hepatocyte apoptosis and necrosis through its contribution to mitochondrial stress, dysregulation of cell signalling pathways and epigenetic regulation.

**INTRODUCTION**

Europe has the highest per capita alcohol consumption and alcohol-related loss of disability adjusted life years globally[1]. The European Union is the heaviest drinking region of the world, with 11 liters of pure alcohol drunk per adult each year[1]. In the last decade, this trend continues to rise in central and northern Europe. Alcohol is a dose-related risk factor for more than 200 diseases[1]. It causes 5.9% of all deaths globally and more than 25% of deaths in the age group 20-39 years[1].

Heavy alcohol use is the cause of alcohol-related liver disease (ALD). Therefore, it is not surprising that the incidence of ALD is on a rising trajectory[2]. The scale of ALD is estimated to burden the United Kingdom national health system with health-related costs of over £3.5 billion per year[2]. In Europe, the cost of treating ALD is estimated to be €17 billion, together with €5bn spent on treatment and prevention of harmful alcohol use and alcohol dependence[3].Worldwide, alcohol-related liver cirrhosis deaths account for approximately10% of all alcohol-attributable deaths resulting in the loss of 22.2 million disability-adjusted life years annually[4].

The ALD spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and cirrhosis. While alcohol-related cirrhosis is no longer considered a completely irreversible condition, no effective anti-fibrotic therapies are currently available. Cirrhosis can be divided into compensated and decompensated stages, with differentiating clinical features and prognosis. The median survival of patients with compensated liver disease is approximately 6.5 years but only 2.5 years in those with decompensated cirrhosis[4]. Once a complication of cirrhosis develops, the 5-year survival rate decreases to less than 20%[4].

Alcoholic hepatitis (AH) is an acute inflammatory condition that occurs on the background of ALD. Severe AH has a mortality rate of 30% within 3 mo[5] but even non-severe AH has a significant 7% mortality within 3 mo[6]. The established treatment for AH is corticosteroids, which improve short-term survival but do not affect long-term survival[5].

The molecular mechanisms underlying ALD pathogenesis are complex and have not been fully elucidated. However, there is emerging evidence that oxidative stress plays a role in mediating the inflammatory response and in directly causing liver damage. Oxidative stress represents the body’s imbalance in the production and the elimination of reactive species (including reactive oxygen and nitrogen species) as well as decreased production of antioxidants[7]. Here, we review the role of oxidative stress in ALD focusing on its effect on mitochondrial stress, cell signaling and epigenetic regulation.

**LITERATURE SEARCH**

Comprehensive searches of MEDLINE, EMBASE, PubMed and TRIPS from their commencement to June 2019 were conducted. The search strategy included subject headings and keywords related to “alcohol” and “oxidative stress” and “liver”. The reference list of all included studies was screened for eligibility. This review included all study types in humans and animals. Studies published in all languages were considered. One author independently screened titles and abstracts and subsequently reviewed full-texts of retrieved studies for eligibility.

**ALCOHOL METABOLISM**

Alcohol (ethanol) is metabolized by three major pathways (Figure 1)[7]. The primary pathway is initiated by alcohol dehydrogenase (ADH), a NAD+ requiring enzyme expressed at high levels in hepatocytes, which oxidizes ethanol to acetaldehyde[7]. In a normal liver, acetaldehyde enters the mitochondria and is quickly metabolized to acetate by aldehyde dehydrogenase (ALDH). Acetate is then broken down to carbon dioxide and water for elimination[8]. In chronic alcohol users, the ADH/ALDH pathway becomes saturated and reactive aldehydes are produced from the metabolism process such as malondialdehyde-acetaldehyde (MAA), 4-hydroxy-2-nonenal (HNE) and lipid hydroperoxides which can bind to proteins to produce protein adducts[8].

These protein adducts are capable of provoking an immune response. *In vitro* experiments showed that the viability of antigen-presenting cells, lymphocytes, and hepatocytes was decreased on incubation with an MAA hen egg lysosome adduct[9]. Circulating antibodies against MAA protein adducts were increased in patients with ALD and AH and correlated with the severity of liver injury[9].

The second major pathway to metabolise ethanol is the microsomal ethanol oxidizing system (MEOS), which involves an NADPH-requiring enzyme, the cytochrome P450 enzyme CYP2E1[10], which is induced by chronic alcohol exposure[11,12]. The increase of CYP2E1 after alcohol intake is due to stabilization of CYP2E1 rather than to a de novo synthesis[11]. The MEOS pathway metabolises ethanol to acetaldehyde by converting NADPH+ and O2 to NADP and H2O resulting in the generation of reactive oxygen species (ROS). CYP2E1 plays a role in lipid peroxidation, protein oxidation, and protein nitration (Figure 1)[11]. It is also known to promote hepatic carcinogenesis by oxidizing DNA in alcohol-exposed rodents[13].

Ethanol metabolism through CYP2E1 not only produces acetaldehyde but also generates ROS including H2O2, hydroxyl (OH-) and carbon centered OH- (Figure 1)[14]. These ROS may be neutralized by a potent antioxidant defense system[14]. However, chronic alcohol consumption disrupts this system; depletion of mitochondrial glutathione (GSH) is observed in patients with alcohol dependence[15], which impairs hepatocyte tolerance to tumour necrosis factor alpha (TNF-α) resulting in an increased likelihood of cell death[16]. ROS increases and activates c-Jun N-terminal kinase (JNK) with consecutive expression of the activator protein 1 (AP-1) transcription factor leading to cellular hyper-regeneration, and lipid peroxidation. Lipid peroxidation products such as malondialdehyde and HNE are generated. HNE can bind to adenosine and cytosine forming highly carcinogenic exocyclic etheno DNA adducts[17]. These DNA adducts have been identified in the livers of patients with ALD and other types of liver disease associated with inflammation and oxidative stress like viral hepatitis[18].

The other two most prevalent DNA adducts are N2-ethyldeoxyguanosine (N2-Et-dG), and 1,N(2)-propano-2′-deoxyguanosine (PdG). N2-Et-dG is detectable in livers of alcohol-exposed mice and leukocytes of human alcohol misusers[19]. PdG, on the other hand, is distinguished by its genotoxic and mutagenic effects which impair DNA replication, thereby triggering cell death. These two major acetaldehyde-DNA adducts also promote carcinogenesis by initiating replication errors and mutations in oncogenes/onco-suppressor genes[19].

A third minor pathway for ethanol metabolism involves catalase, a peroxisomal enzyme (Figure 1)[20], which requires the presence of H2O2, a breakdown product of fatty acids. Catalase located in the peroxisomes of the hepatocyte plays only a minimal role in alcohol metabolism due to low hepatic production of H2O2. Under normal conditions, ADH metabolizes about 75%-80% of the ethanol entering the liver and MEOS the remainder. Hepatic ADH and hepatic catalase activities remain unchanged following chronic alcohol consumption, whereas hepatic MEOS activity strikingly increases and is responsible for the enhanced alcohol metabolism found after chronic alcohol consumption[11,12].

**MITOCHONDRIAL STRESS**

Chronic alcohol consumption results in structural and functional abnormalities in hepatic mitochondria, including enlarged morphology[21,22], mitochondrial DNA (mtDNA) damage[23], reductions in hepatic ATP levels[24] and mitochondrial protein synthesis[25] (Figure 2). This can result in hepatocellular apoptosis and associated necrosis[26]. Chronic alcohol metabolism and associated mitochondrial dysfunction has been implicated in increasing ROS production and accumulation in hepatic mitochondria.

In humans, *in vivo* measurement of ROS is complicated due to their rapid reactions with surrounding molecules[27]. Surrogate measures of mitochondrial-derived ROS include urinary isoprostane levels[28,29], NADH delivery to the respiratory chain[30], lipid peroxidation[31,32] and HNE levels and associated adducts[17,33]. The greatest indicator of ROS overproduction is the increase in hepatic CYP2E1 levels[32,34-37]. The respiratory chain has also been implicated in mitochondrial ROS overproduction in response to chronic alcohol consumption. Excessive levels of reducing equivalents (*e.g*., NADH), produced by alcohol and ADH entering the mitochondrial respiratory chain, lead to electron transport chain reduction, facilitating superoxide anion formation[38,25].

Cell death can be triggered through ROS-induced release of apoptosis signal-regulating kinase 1 (ASK1) (a member of the mitogen-activated protein kinase [MAPK] family), resulting in the cleavage of pro-caspase-3 to active caspase-3, which promotes cellular apoptosis[39-41]. Additionally, cytosolic ASK1 activates MAPK kinase 4 and JNK resulting in increased mitochondrial permeability, mediated by SAB protein, and thus hepatocyte cell death[40,41](Figure 2).

Reactive nitrogen species (RNS) also contribute to mitochondrial damage[22,38]. Alcohol-mediated overproduction of the superoxide anion can result in the generation of RNS, such as peroxynitrite, *via* interaction with nitric oxide, culminating in mitochondrial protein damage[25]. Numerous mitochondrial-localized enzymes involved in respiration and cellular energetic processes are inactivated in this way, including NADH dehydrogenase, succinate dehydrogenase, cytochrome *c* reductase and ATP synthase[42].

To limit oxidative damage following alcohol consumption, hepatic mitochondria have various adaptive mechanisms to prevent functional and structural impairments. Uncoupling proteins (UCPs), specifically UCPs 1-3, reduce ROS production by the uncoupling of mitochondrial oxidative phosphorylation[43], a process observed in patients with non-alcoholic fatty liver disease (NAFLD)[44]. Furthermore, there is mitochondrial upregulation of enzymatic antioxidants catalase, glutathione transferase and heme oxygenase-1 and a marked increase in GSH[45,46]. However, mitochondrial GSH depletion was observed in patients with alcohol dependence and ALD[15,16] suggesting that chronic alcohol exposure downregulates GSH expression.

Manganese-dependent superoxide dismutase (MnSOD) detoxifies mitochondrial superoxide[47], but its response to alcohol is poorly documented. Increased mitochondrial localization of MnSOD was associated with more severe forms of ALD[48], which may be mediated by increased hydroxyl radical generation[22]. Thus, overexpression of MnSOD may be hepatotoxic rather than hepatoprotective.

*S*-adenosylmethionine (SAMe) has been implicated in regulating mitochondrial function, following alcohol consumption in a variety of animal models[49]. SAMe binds and inactivates the catalytic activity of CYP2E1[50], limiting alcohol-dependent increases in mitochondrial production of superoxide[49]. SAMe also increases synthesis and availability of glutathione[51] and maintains mitochondrial respiration rate and mtDNA integrity[38]. Although greater SAMe levels have been observed in the serum of ALD patients compared to healthy subjects[52], a reduction in hepatic SAMe levels was observed in patients with AH[53], suggesting the acute inflammatory state leads to hepatic SAMe depletion. SAMe has been evaluated as a treatment for AH in a recent phase 2 randomized controlled clinical trial. SAMe with prednisolone improved 6-mo survival compared to prednisolone treatment alone[54]. Although these preliminary results are encouraging, a definitive study has yet to be undertaken.

**CELL SIGNALING PATHWAYS**

Lipopolysaccharide (LPS) plays a key role in the pathogenesis of ALD, with higher circulating LPS levels in alcohol dependent patients[55,56]. In AH, LPS predicts organ failure, mortality[57] and infection[58]. Alcohol exposure increases gut permeability, mediating translocation of LPS from the lumen of the intestine to the portal vein into the liver[55]. LPS binds to Toll-like receptor 4 (TLR4) expressed on a wide variety of immune and parenchymal cells including Kupffer cells, hepatocytes, endothelial cells and hepatic stellate cells, initiating one of the primary signaling cascades associated with liver damage[59,60]. LPS-mediated cell signaling results in transcription of pro-inflammatory genes through nuclear factor-κB (NF-κB) and interferon regulatory factor 3 DNA binding[59,61].

Upon LPS stimulation of the TLR4 complex, NADPH oxidase (NOX) 4 interacts with the COOH-terminal region of TLR4 resulting in ROS generation in neutrophils and monocytes[62,63], which directly activates NF-κB[62,64]. ROS-mediated activation and potential regulation of NF-κB activity occurs by several mechanisms: IκB*α* phosphorylation; S-glutathionylation of IKKβ; disruption of I*κ*B ubiquitination and degradation; NF-κB inducing kinase (NIK) activation and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) stimulation[65] (Figure 3). ROS both negatively and positively regulates NF-*κ*B, with oxidative stress in the early phase being a positive regulator, compared to a negative regulator in the late phase[66]. Diphenyliodonium (DPI), an inhibitor of NOX, used as a pre-treatment in alcohol-fed rats, results in normalized ROS production, and inhibition of TNF-α production in Kupffer cells[59,67]. Treatment of alcohol-fed rats with the antioxidant dilinoleoyl-phosphatidylcholine, also inhibited TNF-α production in Kupffer cells and LPS-induced NF-κB activation[68].

Diphenyliodonium and dilinoleoyl-phosphatidylcholine reduce extracellular signal-regulated protein kinase (ERK)1/2 activation[67,68]. LPS-induced activation of ERK1/2 results in transcription of early growth response protein 1 (Egr-1), involved in binding to the TNF-α promoter and increasing TNF-α expression[59]. Egr-1 deficient mice are protected from chronic alcohol-induced liver injury in association with decreased TNF-α messenger RNA (mRNA) levels[69].

LPS activates other MAPKs including p38 and JNK[59], involved in TNF-α production[70]. p38 has been implicated in maintaining the stability of TNF-α mRNA[59,71]. In response to acute alcohol exposure, the JNK pathway has been associated with increased hepatic mitochondrial ROS production[72], increased JNK phosphorylation and AP-1 binding in monocytes[73]. ROS is likely to activate JNK through interaction with upstream MEKK1[65] and by inactivating JNK inhibitor dual specificity protein phosphatase 1[40,74]. ROS have also been associated with activation of cytosolic ASK1[40] (Figure 3). Clinical trials of ASK1 inhibitors as a treatment for inflammatory liver disease are ongoing with a suggestion of reduced fibrosis in patients with NAFLD[75] but no efficacy seen in AH[76].

ROS-mediated S-glutathionylation results in decreased expression of downstream antioxidants such as MnSOD, catalase and Sestrin3 *via* the PI3K/AKT pathway[77]. Akt has also been implicated in increasing oxygen consumption, resulting in elevated mitochondrial generation of H2O2, facilitating further oxidative damage[78,79].

The net result of these alcohol-induced cell signaling pathways is the increased production of pro-inflammatory cytokines through upregulation of transcription factors such as AP-1 and NFκB. TNF-α, a key pro-inflammatory cytokine, is highly elevated in patients with ALD and AH[80-82], with observed TNF-α gene expression increasing in ALD patients[83]. TNF-α induces apoptosis through interaction with TNF-α receptor 1 (TNFR1), initiating a cell-death cascade *via* activation of caspases[84]. In ALD, TNF-α-induces mitochondrial peroxidation[55], which is worsened following depletion of GSH[15,85].

TNF-α exacerbates oxidative damage and inflammation *via* a positive feedback loop. Through association with TNFR1, TNF-α stimulates the association of complex I[86], which culminates in MAPK activation (JNK, p38 and ERK). Complex I also directly contributes to ROS accumulation through generation of superoxide, capable of causing further oxidative damage and eventual TNF-α, perpetuating the cycle[40,87,88].

Soluble inflammatory mediators including interleukins have been implicated in ALD[60,89,90] and are associated with outcome in patients with AH[91]. Elevated serum IL-6 levels have recently been identified as a predictor of mortality in severe AH patients[64]. Hepatic upregulation of IL-6 and IL-1β in ALD, results in the differentiation of naïve CD4+ cells into IL-17-producing T-helper 17 cells (Th17) (Figure 4), resulting in elevated hepatic and serum levels of IL-17 observed in ALD patients[64,92]. IL-17 has a multitude of pro-inflammatory downstream effects, including inducing neutrophil recruitment to the liver; stimulating IL-8 and CXCL1 production by hepatic stellate cells[93] and CXCL4, 5 and 6 expression[92,93]. IL-6 and interferon (IFN)-γ are involved in JAK/STAT activation promoting hepatic regeneration[59,94]. Conversely, despite upregulation of IL-6 in ALD patients, downregulation of STAT activation has been observed in human monocytes with chronic alcohol exposure[95].

Inflammasomes propagate IL-1β and IL-18 signals, important in the regulation of hepatic inflammation[94]. ROS mediates IL-1β and IL-18 signaling *via* inflammasome NLRP3 activation[96,97] and inhibition of antioxidant molecules[41] (Figure 4). Increased production of IL-1β is critical in Th17 differentiation[64,92,98], while IL-18 activates natural killer T-cells (NKTs) to produce IFN-γ[99]. Anti-IL-18 antibodies reduce activation of NF-*κ*B and AP-1, inflammation, liver damage and mortality in animal models[99,100]. IL-1β has also been identified as an activator of MAPKs, including p38, JNK, MEKK1 and IKKβ, involved in mediating upregulation of itself and other pro-inflammatory cytokines[101], creating another positive feedback loop.

**TRACE ELEMENTS**

Trace elements are a group of naturally occurring minerals that are nutritionally fundamental to basic cellular and immunological functions[102]. An essential role of the these molecules, including zinc, copper, selenium and manganese, is to act as cofactors of anti-oxidant enzymes, making their role imperative in the context of oxidative stress[103,104]. Manganese, copper and zinc are part of the SOD enzyme group that catalyze the breakdown of highly reactive superoxide radicals to H2O2 or O2-. Selenium is a component of the active site of glutathione peroxides (GPx), the main function of which is the neutralization of hydrogen peroxide[105]. These enzyme systems are crucial in counterbalancing the oxidative stress state and are impaired in chronic liver disease[106].

Reduced serum levels of trace elements have been confirmed in patients with liver disease, including ALD, and correlate with severity[107-110]. Decreased zinc is associated with liver cirrhosis in alcohol dependent individuals[111] and reduced serum levels of zinc, copper and iron have been observed when compared with healthy controls[112]. Zinc is a crucial trace element involved in multiple cellular and metabolic pathways[113] as well as acting as a cofactor for ALDH. Deficiency or abnormality in zinc function is implicated multiple pathologies, including liver disease (both acute and chronic)[114,115] and is associated with immune dysfunction evidenced by increased inflammation and aberrant immune cell activation[116]. Zinc deficiency in endothelial cells results in increased oxidative stress and decreased inflammatory regulation which is corrected or partially ameliorated by zinc supplementation[117,118]. In alcohol-fed mice, zinc deficiency worsens the balance between hepatic pro- and antioxidant enzymes[119] and is associated with accumulation of ROS in gut epithelial cells and disruption of tight junctions[120]. Given zinc’s influence on antioxidant responses, gut integrity and immune function, a trial of zinc supplementation to improve clinical outcomes in patients with ALD cirrhosis is ongoing (NCT02072746). Preliminary reports suggest zinc supplementation is associated with a reduction in liver inflammation and improvement in immune function[121].

Antioxidant therapy may also have a benefit in the treatment of AH. An antioxidant cocktail (including zinc and selenium) in combination with steroids for the treatment of severe AH correlated with a significant reduction in serum biomarkers, improved short-term prognosis and reduced length of stay in hospital[122]. However, a subsequent study of a complex regimen of N-acetylcysteine (NAC) followed by antioxidant therapy, alone or in conjunction with steroids, reduced renal injury but resulted in no survival benefit over 6 mo[121]. Another clinical trial of steroids combined with NAC in AH showed reduced infection rate but not mortality at 6 mo[123].Antioxidants have also been shown to have a protective effect in patients with NAFLD by reducing serum levels of alanine transaminase (ALT) and spleen size, a finding that likely correlates with an improvement of fatty infiltration[122]. These findings suggest that targeting or counterbalancing oxidative stress in ALD patients may improve patient outcomes.

**EPIGENETICS**

Lifestyle and environmental factors can modify gene expression without altering the DNA sequence, which gets transmitted to the next generation of cells after mitotic division, termed epigenetics[123]. Epigenetic regulation includes both DNA and histone protein modifications as well as action through non-coding micro RNAs[123]. DNA methylation is the most abundant epigenetic modification that directly affects the function of a gene in eukaryotes[124]. Acetylation and deacetylation are modifications in histone proteins carried out by two enzyme families, histone deacetylases (HDACs) and histone acetyl transferase (HAT)[124]. Histone modifying enzymes contribute to the activation or inactivation of transcription by catalyzing the unfolding or further compaction, respectively, of chromatin structure[124].

Excessive ROS is involved in epigenetic gene activation or silencing by changing DNA methylation levels[125]. ROS production induces alterations in DNA methylation patterns and global histone acetylation, which then lead to aberrant gene expression, and may contribute to the process of carcinogenesis[124]. The reduction of global histone acetylation in short term oxidative stress might be due to an immediate increase of class I/II HDAC activity by an unknown mechanism[126,127]. Class III HDAC (Sirtuin NAD+-dependent family of protein deacetylases) has been hypothesized to be upregulated under oxidative stress because NAD+ levels increase in the mitochondria under oxidative stress conditions but direct evidence is lacking[126].

Alcohol consumption increases gene-selective acetylation of histone H3 at lysine 9 (H3K9), levels of enzymes mediating histone acetylation, and results in a generalized increase in DNA methylation[126,127]. These epigenetic-mediated effects of alcohol consumption regulate the inflammatory response, through key pro-inflammatory cytokines, such as TNF-α, which is silenced by H3K9 methylation and activated by H3K9 acetylation[128]. In a macrophage cell line, alcohol treatment resulted in global increased histone H3 and H4 acetylation and specifically increased acetylation of pro-inflammatory gene histones[129].

Oxidative stress itself is an important regulator of epigenetic processes by inhibition of HDAC expression[130]. This takes place *via* activation of PI3Kδ, a signalling molecule controlling many inflammatory signalling pathways[131]. Drugs that inhibit PI3Kδ (*e.g*., theophylline, nortriptyline and specific inhibitors) reduce oxidative stress in *in vitro* and *in vivo* models of lung disease[132]. In patients with AH, there is *in vitro* evidence that theophylline can enhance response to corticosteroid treatment, which may be mediated by its epigenetic effects[133]. Targeting epigenetic regulation has recently been shown to have a beneficial effect in patients with AH; a novel sulphated oxysterol, DUR-928, was well tolerated and improved liver biochemistry in a small phase 2 clinical trial in AH[134].

Activation of the transcription factor Nrf2 is central to cellular defence against ROS[135]. Its negative regulator, kelch-like ECM-associated protein 1 (Keap1), promotes proteasomal degradation of Nrf2. ROS decouples Nrf2 from Keap1, allowing it to translocate to the nucleus to bind to antioxidant response elements (AREs), initiating a range of antioxidant processes[135,136]. Both Nrf2 and Keap1 expression are influenced by epigenetics with evidence of DNA hypermethylation in the Nrf2 promoter[135,136] and Keap1 promoter[137]. Histone acetylation and deacetylation also modify ARE-dependent gene expression with Class 1 HDACs reducing Nrf2[138]. Conversely, HDAC inhibitors restore Nrf2 expression and antioxidant responses. Targeting epigenetic regulation of Nrf2/Keap1 to ameliorate oxidative stress induced inhibition of antioxidant responses is an appealing strategy[138]. However, much of this work has been performed in cancer cell lines and needs further investigation in the context of ALD.

**IMPLICATIONS FOR THERAPY OF ALD**

An improved understanding of the detailed mechanisms by which oxidative stress influences liver damage in patients with ALD may yield new targets for therapy. Current data from pre-clinical and clinical studies suggest potential new avenues for therapy of ALD.

**MITOCHONDRIAL STRESS**

Chronic alcohol consumption results in significant mitochondrial ROS generation leading to morphological and functional changes. Preventing ROS generation may ameliorate this process. Pre-clinical and early phase clinical studies have shown promise of this approach with SAMe. A systematic review and meta-analysis of 11 randomized controlled trials of SAMe treatment for chronic liver disease concluded that it improved liver biochemistry (bilirubin and AST) and had a good safety profile but did not affect mortality[139]. Long term SAMe treatment in patients with ALD does not appear to be clinically effective with no reduction in adverse events or mortality in the two included studies performed in patients with ALD[140,141]. However, short term treatment of the acute mitochondrial stress seen in AH may be a better strategy for the use of SAMe. A phase 2 clinical trial of SAMe with prednisolone for the treatment of severe AH demonstrated improved response rate measured by Lille score and a reduction in hepatorenal syndrome[54]. However, there was no statistically significant difference in 28-d mortality. It may yet prove to be an effective adjunct to anti-inflammatory therapy for AH.

UCPs are strongly associated with mitochondrial stress in ALD. Overexpression of UCP2 reduces apoptosis and oxidative stress *in vitro*[142]. Hepatocellular downregulated mitochondrial carrier protein (HDMCP) expression induced uncoupling and reduced steatosis in an animal model of NAFLD[143]. However, such an approach may promote hepatocyte necrosis and increase the risk of hepatocellular carcinoma[144]. Further studies in this area are required to determine whether targeting UCPs would be a beneficial therapeutic strategy.

**ANTIOXIDANT THERAPY**

NAC, an antioxidant therapy that provides cysteine for glutathione synthesis, has been tested in patients with AH. Although initial trials did not demonstrate a survival benefit[145,146]. a more recent study of NAC in combination with prednisolone, showed a reduction in infective events and 1-month mortality[147]. Therefore, NAC has been suggested for the treatment of AH in clinical practice guidelines, with the caveat that a definitive randomized controlled trial is still required[148].

Deficiency of key trace elements is associated with oxidative stress, which is ameliorated by supplementation. Antioxidant therapy including zinc and other trace elements has shown clinical benefit in patients with AH[122]. However, interpretation is hampered by use of a variety of antioxidants at differing concentrations and durations[145,146]. A trial of long-term zinc supplementation in ALD patients has demonstrated improvements in short-term immune function[149] with long-term clinical outcomes due to be reported shortly. Improved understanding of the role of trace elements in ALD and the optimal formulation and duration of treatment is required.

**EPIGENETIC REGULATION**

Oxidative stress reduces HDAC expression *via* PI3Kδ activation resulting in increased expression of pro-inflammatory genes. Studies targeting HDACs have yet to be performed in patients with ALD. Although *in vitro* studies suggest an antioxidant effect of HDAC inhibition with upregulation of Nrf2 expression[138], HDAC inhibitors approved for use in the treatment of cancer induce cell cycle arrest, apoptosis and oxidative stress in cancer cells which overexpress HDAC[150]. The effect of HDAC inhibitors in the context of ALD requires careful *in vitro* confirmation before clinical translation. However, targeting PI3Kδ is a more appealing strategy with evidence from the respiratory field that specific inhibitors reduce oxidative stress *in vitro* and *in vivo*[132].

**CONCLUSION**

Alcohol is a major global healthcare and economic burden and is a growing cause of chronic liver disease. However, there are currently no effective therapies to treat ALD. Oxidative stress is involved in multiple aspects of ALD pathogenesis (Figure 5). Chronic alcohol consumption results in the saturation of the ADH pathway and increased CYP2E1-mediated alcohol metabolism. This leads to the generation of reactive species including MAA, HNE, lipid hydroperoxides, RNS and ROS, which cause hepatic damage *via* lipid and protein peroxidation, adduct formation and cellular hyper-regulation. Similar damage occurs in hepatic mitochondria with ROS inducing structural and functional damage. ROS cause oxidative damage through multiple mechanisms: promoting cell death *via* protein mediators, increasing and sustaining the upregulation of pro-inflammatory mediators, as well as inducing multiple epigenetic modifications.

**REFERENCES**

1 **Pimpin L**, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L, Sheron N; EASL HEPAHEALTH Steering Committee. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. *J Hepatol* 2018; **69**: 718-735 [PMID: 29777749 DOI: 10.1016/j.jhep.2018.05.011]

2 **Bhattacharya A**. Which cost of alcohol? What should we compare it against? *Addiction* 2017; **112**: 559-565 [PMID: 26970215 DOI: 10.1111/add.13335]

3 **Anderson P**, Baumberg B. Alcohol in Europe-Public Health Perspective: Report summary. *Drugs Educ Prev Policy* 2006; **13**: 483-488 [DOI: 10.1080/09687630600902477]

4 **Ohashi K**, Pimienta M, Seki E. Alcoholic liver disease: A current molecular and clinical perspective. *Liver Res* 2018; **2**: 161-172 [PMID: 31214376 DOI: 10.1016/j.livres.2018.11.002]

5 **Philips CA**, Augustine P, Yerol PK, Rajesh S, Mahadevan P. Severe alcoholic hepatitis: current perspectives. *Hepat Med* 2019; **11**: 97-108 [PMID: 31496843 DOI: 10.2147/HMER.S197933]

6 **Bennett K**, Enki DG, Thursz M, Cramp ME, Dhanda AD. Systematic review with meta-analysis: high mortality in patients with non-severe alcoholic hepatitis. *Aliment Pharmacol Ther* 2019; **50**: 249-257 [PMID: 31231848 DOI: 10.1111/apt.15376]

7 **Li S**, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The Role of Oxidative Stress and Antioxidants in Liver Diseases. *Int J Mol Sci* 2015; **16**: 26087-26124 [PMID: 26540040 DOI: 10.3390/ijms161125942]

8 **Cederbaum AI**, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. *Arch Toxicol* 2009; **83**: 519-548 [PMID: 19448996 DOI: 10.1007/s00204-009-0432-0]

9 **Willis MS**, Klassen LW, Tuma DJ, Sorrell MF, Thiele GM. Adduction of soluble proteins with malondialdehyde-acetaldehyde (MAA) induces antibody production and enhances T-cell proliferation. *Alcohol Clin Exp Res* 2002; **26**: 94-106 [PMID: 11821659 DOI: 10.1111/j.1530-0277.2002.tb02436.x]

10 **Lieber CS**, Rubin E, DeCarli LM. Hepatic microsomal ethanol oxidizing system (MEOS): differentiation from alcohol dehydrogenase and NADPH oxidase. *Biochem Biophys Res Commun* 1970; **40**: 858-865 [PMID: 4395603 DOI: 10.1016/0006-291X(70)90982-4]

11 **Pérez MJ**, Cederbaum AI. Metallothionein 2A induction by zinc protects HEPG2 cells against CYP2E1-dependent toxicity. *Free Radic Biol Med* 2003; **34**: 443-455 [PMID: 12566070 DOI: 10.1016/S0891-5849(02)01302-3]

12 **Weltman MD**, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. *Hepatology* 1998; **27**: 128-133 [PMID: 9425928 DOI: 10.1002/hep.510270121]

13 **Lieber CS**, Seitz HK, Garro AJ, Worner TM. Alcohol-related diseases and carcinogenesis. *Cancer Res* 1979; **39**: 2863-2886 [PMID: 221110]

14 **Seitz HK**, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. *Biol Chem* 2006; **387**: 349-360 [PMID: 16606331 DOI: 10.1515/BC.2006.047]

15 **Albano E**. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. *Mol Aspects Med* 2008; **29**: 9-16 [PMID: 18045675 DOI: 10.1016/j.mam.2007.09.004]

16 **Fernandez-Checa JC**, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. *Toxicol Appl Pharmacol* 2005; **204**: 263-273 [PMID: 15845418 DOI: 10.1016/j.taap.2004.10.001]

17 **Setshedi M**, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. *Oxid Med Cell Longev* 2010; **3**: 178-185 [PMID: 20716942 DOI: 10.4161/oxim.3.3.12288]

18 **Nair J**, Srivatanakul P, Haas C, Jedpiyawongse A, Khuhaprema T, Seitz HK, Bartsch H. High urinary excretion of lipid peroxidation-derived DNA damage in patients with cancer-prone liver diseases. *Mutat Res* 2010; **683**: 23-28 [PMID: 19822158 DOI: 10.1016/j.mrfmmm.2009.10.002]

19 **Abdelmegeed MA**, Choi Y, Ha SK, Song BJ. Cytochrome P450-2E1 promotes aging-related hepatic steatosis, apoptosis and fibrosis through increased nitroxidative stress. *Free Radic Biol Med* 2016; **91**: 188-202 [PMID: 26703967 DOI: 10.1016/j.freeradbiomed.2015.12.016]

20 **Handler JA**, Thurman RG. Hepatic ethanol metabolism is mediated predominantly by catalase-H2O2 in the fasted state. *FEBS Lett* 1988; **238**: 139-141 [PMID: 3169246 DOI: 10.1016/0014-5793(88)80243-6]

21 **Nassir F**, Ibdah JA. Role of mitochondria in alcoholic liver disease. *World J Gastroenterol* 2014; **20**: 2136-2142 [PMID: 24605012 DOI: 10.3748/wjg.v20.i9.2136]

22 **Das SK**, Vasudevan DM. Alcohol-induced oxidative stress. *Life Sci* 2007; **81**: 177-187 [PMID: 17570440 DOI: 10.1016/j.lfs.2007.05.005]

23 **Venkatraman A**, Landar A, Davis AJ, Chamlee L, Sanderson T, Kim H, Page G, Pompilius M, Ballinger S, Darley-Usmar V, Bailey SM. Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. *J Biol Chem* 2004; **279**: 22092-22101 [PMID: 15033988 DOI: 10.1074/jbc.M402245200]

24 **Grattagliano I**, Russmann S, Diogo C, Bonfrate L, Oliveira PJ, Wang DQ, Portincasa P. Mitochondria in chronic liver disease. *Curr Drug Targets* 2011; **12**: 879-893 [PMID: 21269263 DOI: 10.2174/138945011795528877]

25 **García-Ruiz C**, Kaplowitz N, Fernandez-Checa JC. Role of Mitochondria in Alcoholic Liver Disease. *Curr Pathobiol Rep* 2013; **1**: 159-168 [PMID: 25343061 DOI: 10.1007/s40139-013-0021-z]

26 **Hoek JB**, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. *Gastroenterology* 2002; **122**: 2049-2063 [PMID: 12055609 DOI: 10.1053/gast.2002.33613]

27 **Beier JI**, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. *Biol Chem* 2010; **391**: 1249-1264 [PMID: 20868231 DOI: 10.1515/BC.2010.137]

28 **Meagher EA**, Barry OP, Burke A, Lucey MR, Lawson JA, Rokach J, FitzGerald GA. Alcohol-induced generation of lipid peroxidation products in humans. *J Clin Invest* 1999; **104**: 805-813 [PMID: 10491416 DOI: 10.1172/JCI5584]

29 **Morrow JD**. The isoprostanes: their quantification as an index of oxidant stress status in vivo. *Drug Metab Rev* 2000; **32**: 377-385 [PMID: 11139135 DOI: 10.1081/DMR-100102340]

30 **Mantena SK**, King AL, Andringa KK, Landar A, Darley-Usmar V, Bailey SM. Novel interactions of mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver disease. *World J Gastroenterol* 2007; **13**: 4967-4973 [PMID: 17854139 DOI: 10.3748/wjg.v13.i37.4967]

31 **Ekström G**, Ingelman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). *Biochem Pharmacol* 1989; **38**: 1313-1319 [PMID: 2495801 DOI: 10.1016/0006-2952(89)90338-9]

32 **Seth D**, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. *J Gastroenterol Hepatol* 2011; **26**: 1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]

33 **Roede JR**, Jones DP. Reactive species and mitochondrial dysfunction: mechanistic significance of 4-hydroxynonenal. *Environ Mol Mutagen* 2010; **51**: 380-390 [PMID: 20544880 DOI: 10.1002/em.20553]

34 **Niemelä O**, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. *J Hepatol* 2000; **33**: 893-901 [PMID: 11131450 DOI: 10.1016/S0168-8278(00)80120-8]

35 **Takahashi T**, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. *Hepatology* 1993; **17**: 236-245 [PMID: 8428720 DOI: 10.1002/hep.1840170213]

36 **Yun JW**, Son MJ, Abdelmegeed MA, Banerjee A, Morgan TR, Yoo SH, Song BJ. Binge alcohol promotes hypoxic liver injury through a CYP2E1-HIF-1α-dependent apoptosis pathway in mice and humans. *Free Radic Biol Med* 2014; **77**: 183-194 [PMID: 25236742 DOI: 10.1016/j.freeradbiomed.2014.08.030]

37 **Adam-Vizi V**. Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources. *Antioxid Redox Signal* 2005; **7**: 1140-1149 [PMID: 16115017 DOI: 10.1089/ars.2005.7.1140]

38 **Manzo-Avalos S**, Saavedra-Molina A. Cellular and mitochondrial effects of alcohol consumption. *Int J Environ Res Public Health* 2010; **7**: 4281-4304 [PMID: 21318009 DOI: 10.3390/ijerph7124281]

39 **Harijith A**, Ebenezer DL, Natarajan V. Reactive oxygen species at the crossroads of inflammasome and inflammation. *Front Physiol* 2014; **5**: 352 [PMID: 25324778 DOI: 10.3389/fphys.2014.00352]

40 **Seki E**, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. *Gastroenterology* 2012; **143**: 307-320 [PMID: 22705006 DOI: 10.1053/j.gastro.2012.06.004]

41 **Gunawan BK**, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. *Gastroenterology* 2006; **131**: 165-178 [PMID: 16831600 DOI: 10.1053/j.gastro.2006.03.045]

42 **Pacher P**, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 2007; **87**: 315-424 [PMID: 17237348 DOI: 10.1152/physrev.00029.2006]

43 **Mailloux RJ**, Harper ME. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. *Free Radic Biol Med* 2011; **51**: 1106-1115 [PMID: 21762777 DOI: 10.1016/j.freeradbiomed.2011.06.022]

44 **Chavin KD**, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Biol Chem* 1999; **274**: 5692-5700 [PMID: 10026188 DOI: 10.1074/jbc.274.9.5692]

45 **Cederbaum AI**. Cytochrome P450 2E1-dependent oxidant stress and upregulation of anti-oxidant defense in liver cells. *J Gastroenterol Hepatol* 2006; **21** Suppl 3: S22-S25 [PMID: 16958665 DOI: 10.1111/j.1440-1746.2006.04595.x]

46 **Marí M**, Cederbaum AI. CYP2E1 overexpression in HepG2 cells induces glutathione synthesis by transcriptional activation of gamma-glutamylcysteine synthetase. *J Biol Chem* 2000; **275**: 15563-15571 [PMID: 10748080 DOI: 10.1074/jbc.M907022199]

47 **Candas D**, Li JJ. MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx. *Antioxid Redox Signal* 2014; **20**: 1599-1617 [PMID: 23581847 DOI: 10.1089/ars.2013.5305]

48 **Degoul F**, Sutton A, Mansouri A, Cepanec C, Degott C, Fromenty B, Beaugrand M, Valla D, Pessayre D. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. *Gastroenterology* 2001; **120**: 1468-1474 [PMID: 11313317 DOI: 10.1053/gast.2001.24051]

49 **Andringa KK**, King AL, Eccleston HB, Mantena SK, Landar A, Jhala NC, Dickinson DA, Squadrito GL, Bailey SM. Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. *Am J Physiol Gastrointest Liver Physiol* 2010; **298**: G732-G745 [PMID: 20150243 DOI: 10.1152/ajpgi.00332.2009]

50 **Cederbaum AI**. Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. *World J Gastroenterol* 2010; **16**: 1366-1376 [PMID: 20238404 DOI: 10.3748/wjg.v16.i11.1366]

51 **Fernández-Checa JC**, Colell A, García-Ruiz C. S-Adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease. *Alcohol* 2002; **27**: 179-183 [PMID: 12163147 DOI: 10.1016/S0741-8329(02)00229-X]

52 **Mudd SH**, Wagner C, Luka Z, Stabler SP, Allen RH, Schroer R, Wood T, Wang J, Wong LJ. Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine. *Mol Genet Metab* 2012; **105**: 228-236 [PMID: 22137549 DOI: 10.1016/j.ymgme.2011.11.006]

53 **Lee TD**, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. *Alcohol Clin Exp Res* 2004; **28**: 173-181 [PMID: 14745316 DOI: 10.1097/01.ALC.0000108654.77178.03]

54 **Tkachenko P**, Maevskaya M, Pavlov A, Komkova I, Pavlov C, Ivashkin V. Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis. *Hepatol Int* 2016; **10**: 983-987 [PMID: 27337960 DOI: 10.1007/s12072-016-9751-4]

55 **Lucey MR**, Mathurin P, Morgan TR. Alcoholic hepatitis. *N Engl J Med* 2009; **360**: 2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]

56 **Fujimoto M**, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, Kitano H, Kikukawa M, Ann T, Ishii Y, Kojima H, Sakurai S, Tanaka R, Namisaki T, Noguchi R, Higashino T, Kikuchi E, Nishimura K, Takaya A, Fukui H. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. *Alcohol Clin Exp Res* 2000; **24**: 48S-54S [PMID: 10803780 DOI: 10.1111/j.1530-0277.2000.tb00012.x]

57 **Michelena J**, Altamirano J, Abraldes JG, Affò S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, García-Pagán JC, Fernández J, Arroyo V, Ginès P, Louvet A, Mathurin P, Mehal WZ, Caballería J, Bataller R. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology* 2015; **62**: 762-772 [PMID: 25761863 DOI: 10.1002/hep.27779]

58 **Vergis N**, Atkinson SR, Knapp S, Maurice J, Allison M, Austin A, Forrest EH, Masson S, McCune A, Patch D, Richardson P, Gleeson D, Ryder SD, Wright M, Thursz MR. In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. *Gastroenterology* 2017; **152**: 1068-1077.e4 [PMID: 28043903 DOI: 10.1053/j.gastro.2016.12.019]

59 **Mandrekar P**, Szabo G. Signalling pathways in alcohol-induced liver inflammation. *J Hepatol* 2009; **50**: 1258-1266 [PMID: 19398236 DOI: 10.1016/j.jhep.2009.03.007]

60 **Seki E**, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. *Hepatology* 2008; **48**: 322-335 [PMID: 18506843 DOI: 10.1002/hep.22306]

61 **Li P**, He K, Li J, Liu Z, Gong J. The role of Kupffer cells in hepatic diseases. *Mol Immunol* 2017; **85**: 222-229 [PMID: 28314211 DOI: 10.1016/j.molimm.2017.02.018]

62 **Park HS**, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. *J Immunol* 2004; **173**: 3589-3593 [PMID: 15356101 DOI: 10.4049/jimmunol.173.6.3589]

63 **Petrasek J**, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. *Gastroenterol Res Pract* 2010; **2010**: 710381 [PMID: 20827314 DOI: 10.1155/2010/710381]

64 **Shasthry SM**, Sarin SK. New treatment options for alcoholic hepatitis. *World J Gastroenterol* 2016; **22**: 3892-3906 [PMID: 27099434 DOI: 10.3748/wjg.v22.i15.3892]

65 **Zhang J**, Wang X, Vikash V, Ye Q, Wu D, Liu Y, Dong W. ROS and ROS-Mediated Cellular Signaling. *Oxid Med Cell Longev* 2016; **2016**: 4350965 [PMID: 26998193 DOI: 10.1155/2016/4350965]

66 **Mu W**, Liu LZ. Reactive Oxygen Species Signaling in Cancer Development. *React Oxyg Species* 2017; **4**: 251-265

67 **Thakur V**, Pritchard MT, McMullen MR, Wang Q, Nagy LE. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. *J Leukoc Biol* 2006; **79**: 1348-1356 [PMID: 16554353 DOI: 10.1189/jlb.1005613]

68 **Cao Q**, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. *Biochem Biophys Res Commun* 2002; **299**: 459-464 [PMID: 12445823 DOI: 10.1016/S0006-291X(02)02672-4]

69 **McMullen MR**, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. *Gastroenterology* 2005; **128**: 2066-2076 [PMID: 15940638 DOI: 10.1053/j.gastro.2005.02.065]

70 **Yao J**, Mackman N, Edgington TS, Fan ST. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. *J Biol Chem* 1997; **272**: 17795-17801 [PMID: 9211933 DOI: 10.1074/jbc.272.28.17795]

71 **Kishore R**, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway. *J Biol Chem* 2001; **276**: 41930-41937 [PMID: 11551956 DOI: 10.1074/jbc.M107181200]

72 **Win S**, Than TA, Zhang J, Oo C, Min RWM, Kaplowitz N. New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases. *Hepatology* 2018; **67**: 2013-2024 [PMID: 29194686 DOI: 10.1002/hep.29689]

73 **Oak S**, Mandrekar P, Catalano D, Kodys K, Szabo G. TLR2- and TLR4-mediated signals determine attenuation or augmentation of inflammation by acute alcohol in monocytes. *J Immunol* 2006; **176**: 7628-7635 [PMID: 16751410 DOI: 10.4049/jimmunol.176.12.7628]

74 **Chang Q**, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, Shi X, Chen F. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. *J Hepatol* 2009; **50**: 323-333 [PMID: 19041150 DOI: 10.1016/j.jhep.2008.07.037]

75 **Loomba R**, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. *Hepatology* 2018; **67**: 549-559 [PMID: 28892558 DOI: 10.1002/hep.29514]

76 **Mathurin P**, Dufour J‐F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, Billin A, Chung C, Subramanian M, Myers RP, Szabo G, Thevenot T, Cramp ME, Ryder SD, Tilg H, Moreno C, Thursz MR, Agarwal K. Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial. *Hepatology* 2018; **68**; 8A-9A [DOI: 10.1002/hep.30256]

77 **Nogueira V**, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. *Clin Cancer Res* 2013; **19**: 4309-4314 [PMID: 23719265 DOI: 10.1158/1078-0432.CCR-12-1424]

78 **Zhang Y**, Du Y, Le W, Wang K, Kieffer N, Zhang J. Redox control of the survival of healthy and diseased cells. *Antioxid Redox Signal* 2011; **15**: 2867-2908 [PMID: 21457107 DOI: 10.1089/ars.2010.3685]

79 **Zhao Y**, Hu X, Liu Y, Dong S, Wen Z, He W, Zhang S, Huang Q, Shi M. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. *Mol Cancer* 2017; **16**: 79 [PMID: 28407774 DOI: 10.1186/s12943-017-0648-1]

80 **Latvala J**, Hietala J, Koivisto H, Järvi K, Anttila P, Niemelä O. Immune Responses to Ethanol Metabolites and Cytokine Profiles Differentiate Alcoholics with or without Liver Disease. *Am J Gastroenterol* 2005; **100**: 1303-1310 [PMID: 15929761 DOI: 10.1111/j.1572-0241.2005.41509.x]

81 **Bird GL**, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. *Ann Intern Med* 1990; **112**: 917-920 [PMID: 2339855 DOI: 10.7326/0003-4819-112-12-917]

82 **Szabo G**, Bala S. Alcoholic liver disease and the gut-liver axis. *World J Gastroenterol* 2010; **16**: 1321-1329 [PMID: 20238398 DOI: 10.3748/wjg.v16.i11.1321]

83 **Colmenero J**, Bataller R, Sancho-Bru P, Bellot P, Miquel R, Moreno M, Jares P, Bosch J, Arroyo V, Caballería J, Ginès P. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. *Gastroenterology* 2007; **132**: 687-697 [PMID: 17258719 DOI: 10.1053/j.gastro.2006.12.036]

84 **McVicker BL**, Tuma DJ, Casey CA. Effect of ethanol on pro-apoptotic mechanisms in polarized hepatic cells. *World J Gastroenterol* 2007; **13**: 4960-4966 [PMID: 17854138 DOI: 10.3748/wjg.v13.i37.4960]

85 **Neuman MG**, Shear NH, Bellentani S, Tiribelli C. Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. *Gastroenterology* 1998; **115**: 157-166 [PMID: 9649471 DOI: 10.1016/S0016-5085(98)70377-4]

86 **Micheau O**, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell* 2003; **114**: 181-190 [PMID: 12887920 DOI: 10.1016/S0092-8674(03)00521-X]

87 **Kim YS**, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. *Mol Cell* 2007; **26**: 675-687 [PMID: 17560373 DOI: 10.1016/j.molcel.2007.04.021]

88 **Vanden Berghe T**, Declercq W, Vandenabeele P. NADPH oxidases: new players in TNF-induced necrotic cell death. *Mol Cell* 2007; **26**: 769-771 [PMID: 17588511 DOI: 10.1016/j.molcel.2007.06.002]

89 **Minayoshi Y**, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. *Drug Deliv* 2018; **25**: 1067-1077 [PMID: 29688069 DOI: 10.1080/10717544.2018.1464083]

90 **Sun B**, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. *Oncogene* 2008; **27**: 6228-6244 [PMID: 18931690 DOI: 10.1038/onc.2008.300]

91 **Dhanda AD**, Yates E, Schewitz-Bowers LP, Lait PJ, Lee RWJ, Cramp ME. *Ex Vivo* T Cell Cytokine Expression Predicts Survival in Patients with Severe Alcoholic Hepatitis. *Gut Liver* 2020; **14**: 265-268 [PMID: 31158952 DOI: 10.5009/gnl19035]

92 **Lemmers A**, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. *Hepatology* 2009; **49**: 646-657 [PMID: 19177575 DOI: 10.1002/hep.22680]

93 **Orman ES**, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. *J Gastroenterol Hepatol* 2013; **28** Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]

94 **Kerr IM**, Costa-Pereira AP, Lillemeier BF, Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and trains. *FEBS Lett* 2003; **546**: 1-5 [PMID: 12829228 DOI: 10.1016/S0014-5793(03)00411-3]

95 **Norkina O**, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes. *Alcohol Clin Exp Res* 2008; **32**: 1565-1573 [PMID: 18616672 DOI: 10.1111/j.1530-0277.2008.00726.x]

96 **Tilg H**, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology* 2016; **64**: 955-965 [PMID: 26773297 DOI: 10.1002/hep.28456]

97 **Tschopp J**, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? *Nat Rev Immunol* 2010; **10**: 210-215 [PMID: 20168318 DOI: 10.1038/nri2725]

98 **Revu S**, Wu J, Henkel M, Rittenhouse N, Menk A, Delgoffe GM, Poholek AC, McGeachy MJ. IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. *Cell Rep* 2018; **22**: 2642-2653 [PMID: 29514093 DOI: 10.1016/j.celrep.2018.02.044]

99 **Szabo G**, Csak T. Inflammasomes in liver diseases. *J Hepatol* 2012; **57**: 642-654 [PMID: 22634126 DOI: 10.1016/j.jhep.2012.03.035]

100 **Takeuchi D**, Yoshidome H, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Morita Y, Miyazaki M. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. *Hepatology* 2004; **39**: 699-710 [PMID: 14999688 DOI: 10.1002/hep.20117]

101 **Sakai A**, Han J, Cato AC, Akira S, Li JD. Glucocorticoids synergize with IL-1beta to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells. *BMC Mol Biol* 2004; **5**: 2 [PMID: 15125785 DOI: 10.1186/1471-2199-5-2]

102 **Wintergerst ES**, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. *Ann Nutr Metab* 2007; **51**: 301-323 [PMID: 17726308 DOI: 10.1159/000107673]

103 **Zhu H**, Jia Z, Misra H, Li YR. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. *J Dig Dis* 2012; **13**: 133-142 [PMID: 22356308 DOI: 10.1111/j.1751-2980.2011.00569.x]

104 **Shah D**, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus. *J Biomed Sci* 2014; **21**: 23 [PMID: 24636579 DOI: 10.1186/1423-0127-21-23]

105 **Wołonciej M**, Milewska E, Roszkowska-Jakimiec W. Trace elements as an activator of antioxidant enzymes. *Postepy Hig Med Dosw (Online)* 2016; **70**: 1483-1498 [PMID: 28100855 DOI: 10.5604/17322693.1229074]

106 **Czuczejko J**, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J. Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases. *Acta Biochim Pol* 2003; **50**: 1147-1154 [PMID: 14740001 DOI: 10.18388/abp.2003\_3638]

107 **Arakawa Y**, Moriyama M, Arakawa Y. Liver cirrhosis and metabolism (sugar, protein, fat and trace elements). *Hepatol Res* 2004; **30S**: 46-58 [PMID: 15607139 DOI: 10.1016/j.hepres.2004.10.009]

108 **Nangliya V**, Sharma A, Yadav D, Sunder S, Nijhawan S, Mishra S. Study of trace elements in liver cirrhosis patients and their role in prognosis of disease. *Biol Trace Elem Res* 2015; **165**: 35-40 [PMID: 25613584 DOI: 10.1007/s12011-015-0237-3]

109 **Burk RF**, Hill KE, Motley AK, Byrne DW, Norsworthy BK. Selenium deficiency occurs in some patients with moderate-to-severe cirrhosis and can be corrected by administration of selenate but not selenomethionine: a randomized controlled trial. *Am J Clin Nutr* 2015; **102**: 1126-1133 [PMID: 26468123 DOI: 10.3945/ajcn.115.110932]

110 **Prystupa A**, Błażewicz A, Kiciński P, Sak JJ, Niedziałek J, Załuska W. Serum Concentrations of Selected Heavy Metals in Patients with Alcoholic Liver Cirrhosis from the Lublin Region in Eastern Poland. *Int J Environ Res Public Health* 2016; **13**: 582 [PMID: 27304961 DOI: 10.3390/ijerph13060582]

111 **Huang MC**, Chen CH, Peng FC, Tang SH, Chen CC. Alterations in oxidative stress status during early alcohol withdrawal in alcoholic patients. *J Formos Med Assoc* 2009; **108**: 560-569 [PMID: 19586830 DOI: 10.1016/S0929-6646(09)60374-0]

112 **Saribal D**, Hocaoglu-Emre FS, Karaman F, Mırsal H, Akyolcu MC. Trace Element Levels and Oxidant/Antioxidant Status in Patients with Alcohol Abuse. *Biol Trace Elem Res* 2020; **193**: 7-13 [PMID: 30805875 DOI: 10.1007/s12011-019-01681-y]

113 **Grüngreiff K**, Reinhold D, Wedemeyer H. The role of zinc in liver cirrhosis. *Ann Hepatol* 2016; **15**: 7-16 [PMID: 26626635 DOI: 10.5604/16652681.1184191]

114 **Bode JC**, Hanisch P, Henning H, Koenig W, Richter FW, Bode C. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. *Hepatology* 1988; **8**: 1605-1609 [PMID: 3192174 DOI: 10.1002/hep.1840080622]

115 **Tapiero H**, Tew KD. Trace elements in human physiology and pathology: zinc and metallothioneins. *Biomed Pharmacother* 2003; **57**: 399-411 [PMID: 14652165 DOI: 10.1016/S0753-3322(03)00081-7]

116 **Wong CP**, Rinaldi NA, Ho E. Zinc deficiency enhanced inflammatory response by increasing immune cell activation and inducing IL6 promoter demethylation. *Mol Nutr Food Res* 2015; **59**: 991-999 [PMID: 25656040 DOI: 10.1002/mnfr.201400761]

117 **Hennig B**, Meerarani P, Toborek M, McClain CJ. Antioxidant-like properties of zinc in activated endothelial cells. *J Am Coll Nutr* 1999; **18**: 152-158 [PMID: 10204831 DOI: 10.1080/07315724.1999.10718843]

118 **Shen H**, Arzuaga X, Toborek M, Hennig B. Zinc nutritional status modulates expression of ahr-responsive p450 enzymes in vascular endothelial cells. *Environ Toxicol Pharmacol* 2008; **25**: 197-201 [PMID: 19255596 DOI: 10.1016/j.etap.2007.10.016]

119 **Zhong W**, Zhao Y, Sun X, Song Z, McClain CJ, Zhou Z. Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors. *PLoS One* 2013; **8**: e76522 [PMID: 24155903 DOI: 10.1371/journal.pone.0076522]

120 **Zhong W**, McClain CJ, Cave M, Kang YJ, Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. *Am J Physiol Gastrointest Liver Physiol* 2010; **298**: G625-G633 [PMID: 20167873 DOI: 10.1152/ajpgi.00350.2009]

121 **Mohammad MK**, Song M, Falkner K, McClain C, Cave M. Zinc Sulfate for Alcoholic Cirrhosis (ZAC) Clinical Trial - Interim Analysis of Fiver Injury/Inflammation Biomarkers. *Hepatology* 2014; **60**: 794A [DOI: 10.1002/hep.28229]

122 **Wenzel G**, Kuklinski B, Rühlmann C, Ehrhardt D. [Alcohol-induced toxic hepatitis--a "free radical" associated disease. Lowering fatality by adjuvant antioxidant therapy]. *Z Gesamte Inn Med* 1993; **48**: 490-496 [PMID: 8256468]

123 **Pár A**, Pár G. [Alcoholic liver disease: the roles of genetic-epigenetic factors and the effect of abstinence]. *Orv Hetil* 2019; **160**: 524-532 [PMID: 30931596 DOI: 10.1556/650.2019.31352]

124 **Wu Q**, Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. *Curr Drug Targets* 2015; **16**: 13-19 [PMID: 25585126 DOI: 10.2174/1389450116666150113121054]

125 **Afanas'ev I**. New nucleophilic mechanisms of ros-dependent epigenetic modifications: comparison of aging and cancer. *Aging Dis* 2014; **5**: 52-62 [PMID: 24490117 DOI: 10.14336/AD.2014.050052]

126 **Boccuto L**, Abenavoli L. Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. *Ann Hepatol* 2017; **16**: 490-500 [PMID: 28612750 DOI: 10.5604/01.3001.0010.0274]

127 **Meroni M**, Longo M, Rametta R, Dongiovanni P. Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. *Int J Mol Sci* 2018; **19**: 3857 [PMID: 30513996 DOI: 10.3390/ijms19123857]

128 **Zahs A**, Curtis BJ, Waldschmidt TJ, Brown LA, Gauthier TW, Choudhry MA, Kovacs EJ, Bird MD. Alcohol and epigenetic changes: summary of the 2011 Alcohol and Immunology Research Interest Group (AIRIG) meeting. *Alcohol* 2012; **46**: 783-787 [PMID: 22738858 DOI: 10.1016/j.alcohol.2012.05.005]

129 **Kendrick SF**, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DE, Day CP. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. *Hepatology* 2010; **51**: 1988-1997 [PMID: 20232292 DOI: 10.1002/hep.23572]

130 **To Y**, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliott WM, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; **182**: 897-904 [PMID: 20224070 DOI: 10.1164/rccm.200906-0937OC]

131 **Ito K**, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. *J Pharmacol Exp Ther* 2007; **321**: 1-8 [PMID: 17021257 DOI: 10.1124/jpet.106.111674]

132 **Barnes PJ**. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2013; **131**: 636-645 [PMID: 23360759 DOI: 10.1016/j.jaci.2012.12.1564]

133 **Kendrick SF**, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. *Hepatology* 2010; **52**: 126-131 [PMID: 20578267 DOI: 10.1002/hep.23666]

134 **Hassanein T**, Stein LL, Flamm SL, Martin P, Cave MC, Blevins C, Scott, D, Krebs W, Lin W. Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis. *Hepatology* 2019; **70**: 1477A-1501A [DOI: 10.1002/hep.31033]

135 **Yu S**, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. *PLoS One* 2010; **5**: e8579 [PMID: 20062804 DOI: 10.1371/journal.pone.0008579]

136 **Khor TO**, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, Kong AN. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. *Cancer Prev Res (Phila)* 2014; **7**: 1186-1197 [PMID: 25266896 DOI: 10.1158/1940-6207.CAPR-14-0127]

137 **Wang D**, Ma Y, Yang X, Xu X, Zhao Y, Zhu Z, Wang X, Deng H, Li C, Gao F, Tong J, Yamanaka K, An Y. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation. *Free Radic Biol Med* 2015; **89**: 209-219 [PMID: 26409248 DOI: 10.1016/j.freeradbiomed.2015.07.153]

138 **Correa F**, Mallard C, Nilsson M, Sandberg M. Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β. *Neurobiol Dis* 2011; **44**: 142-151 [PMID: 21757005 DOI: 10.1016/j.nbd.2011.06.016]

139 **Guo T**, Chang L, Xiao Y, Liu Q. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. *PLoS One* 2015; **10**: e0122124 [PMID: 25774783 DOI: 10.1371/journal.pone.0122124]

140 **Medici V**, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF 3rd, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. *Alcohol Clin Exp Res* 2011; **35**: 1960-1965 [PMID: 22044287 DOI: 10.1111/j.1530-0277.2011.01547.x]

141 **Mato JM**, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. *J Hepatol* 1999; **30**: 1081-1089 [PMID: 10406187 DOI: 10.1016/S0168-8278(99)80263-3]

142 **Collins P**, Jones C, Choudhury S, Damelin L, Hodgson H. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. *Liver Int* 2005; **25**: 880-887 [PMID: 15998440 DOI: 10.1111/j.1478-3231.2005.01104.x]

143 **Jin X**, Yang YD, Chen K, Lv ZY, Zheng L, Liu YP, Chen SH, Yu CH, Jiang XY, Zhang CY, Li YM. HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: a novel mechanism for NAFLD. *J Hepatol* 2009; **50**: 1019-1028 [PMID: 19303656 DOI: 10.1016/j.jhep.2008.10.034]

144 **Cortez-Pinto H**, Machado MV. Uncoupling proteins and non-alcoholic fatty liver disease. *J Hepatol* 2009; **50**: 857-860 [PMID: 19328582 DOI: 10.1016/j.jhep.2009.02.019]

145 **Phillips M**, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. *J Hepatol* 2006; **44**: 784-790 [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]

146 **Stewart S**, Prince M, Bassendine M, Hudson M, James O, Jones D, Record C, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. *J Hepatol* 2007; **47**: 277-283 [PMID: 17532088 DOI: 10.1016/j.jhep.2007.03.027]

147 **Nguyen-Khac E**, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. *N Engl J Med* 2011; **365**: 1781-1789 [PMID: 22070475 DOI: 10.1056/NEJMoa1101214]

148 **European Association for the Study of the Liver**; Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, Sterneck M, Cortez-Pinto H. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. *J Hepatol* 2018; **69**: 154-181 [PMID: 29628280 DOI: 10.1016/j.jhep.2018.03.018]

149 **McClain C**, Vatsalya V, Cave M. Role of Zinc in the Development/Progression of Alcoholic Liver Disease. *Curr Treat Options Gastroenterol* 2017; **15**: 285-295 [PMID: 28447197 DOI: 10.1007/s11938-017-0132-4]

150 **Singh AK**, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. *Nutrients* 2018; **10**: 731 [PMID: 29882797 DOI: 10.3390/nu10060731]

**Footnotes**

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 31, 2019

**First decision:** February 19, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P- Reviewer:** Conti CB, Fujii J **S- Editor:** Yan JP **L- Editor:** **E- Editor:**

**Figure Legends**

**手机屏幕截图

描述已自动生成**

**Figure 1 The three major pathways of alcohol metabolism.** The primary pathway is initiated by alcohol dehydrogenase, a NAD+ requiring enzyme expressed at high levels in hepatocytes, which oxidizes ethanol to acetaldehyde. The second major pathway, the microsomal ethanol oxidizing system pathway, involves the NADPH-requiring enzyme cytochrome P450 enzyme 2E1, which is induced by chronic alcohol exposure. The third pathway for ethanol metabolism is carried out by catalase, a peroxisomal enzyme. ADH: Alcohol dehydrogenase; ALDH2: Aldehyde dehydrogenase; CYP2E1: Cytochrome P450 enzyme 2E1; HNE: 4-hydroxy-2-nonenal; LOOH: Lipid hydroperoxides; MDA: Malondialdehyde; MEOS: Microsomal ethanol oxidizing system; ROS: Reactive oxygen species.

地图上有字

描述已自动生成

**Figure 2 Pathways involved in mediating mitochondrial oxidative stress.** Alcohol elevates mitochondrial cytochrome p450 2E1 and NADH levels facilitating reactive oxygen species (ROS) upregulation. Elevated ROS damages mitochondrial DNA, proteins and cristae and causes a reduction in mitochondrial ATP and glutathione. ROS-activated thioredoxin-interacting protein translocates to mitochondria binding thioredoxin 2, indirectly producing further ROS through inhibiting its antioxidant activity. Apoptosis signal-regulating kinase 1 liberated from thioredoxin 2, facilitates cleavage of pro-caspase 3 to caspase 3 leading to hepatocellular apoptosis. Mitochondrial ROS activates cytosolic apoptosis signal-regulating kinase 1 leading to downstream opening of the mitochondrial transition pore through mitogen-activated protein kinase kinase 4 and c-Jun N-terminal kinase activation. ROS form reactive nitrogen species which inhibit mitochondrial enzymes. ASK1: Apoptosis signal-regulating kinase 1; BAX: Bcl-2-associated X protein; CYP2E1: Cytochrome p450 2E1; ETC: Electron transport chain; GSH: Glutathione; JNK: C-Jun N-terminal kinase; MKK4: Mitogen-activated protein kinase kinase 4; mtDNA: Mitochondrial DNA; ROS: Reactive oxygen species; RNS: Reactive nitrogen species; SAB: SH3 domain-binding protein that preferentially associates with Btk; TRX2: Thioredoxin 2; TXNIP: Thioredoxin-interacting protein.

地图的截图

描述已自动生成

**Figure 3 Signaling pathways involved in exacerbating oxidative damage and liver injury.** Lipopolysaccharide, alcohol and extracellular reactive oxygen species (ROS) are all capable of activating toll-like receptor 4 leading to myeloid differentiation primary response 88 (MyD88) activation. MyD88 association with interleukin-1 receptor-associated kinase 1-4 results in activation of the tumor necrosis factor receptor-associated factor 6/transforming growth factor beta-activated kinase 1 complex, which activates MAPKs c-Jun N-terminal kinase, p38 and extracellular signal-regulated protein kinase, facilitating transcription factors activator protein 1 and early growth response protein 1 to translocate to the nucleus and upregulate pro-inflammatory mediators. Tumor necrosis factor receptor-associated factor 6/transforming growth factor beta-activated kinase 1-mediated phosphorylation of the IKKα-β-γ complex leads to IκB phosphorylation and nuclear factor κB (NF-κB) translocation to the nucleus to upregulate pro-inflammatory cytokines. MyD88 signaling also activates NADPH oxidase 4 to produces ROS. ROS are also produced by the NADPH oxidase 1/ras-related C3 botulinum toxin substrate 1 complex which is activated upstream by tumour necrosis factor alpha interacting with tumour necrosis factor alpha receptor type 1, at the cell surface, which activates complex I. ROS upregulate NF-κB translocation to the nucleus through IκB phosphorylation, nuclear factor κB inducing kinase activation and indirect protein kinase B activation. At high concentrations, ROS inhibit NF-κB activation through inhibition of IκB phosphorylation and S-glutathionylation of IKKβ. ROS inhibit dual specificity protein phosphatase 1 and thioredoxin to further upregulate the c-Jun N-terminal kinase pathway. ROS inactivation of phosphatase and tensin homolog facilitates phosphoinositide 3-kinase to produce protein kinase B, which elevates ROS levels via increased oxygen consumption, and inactivates forkhead box protein O and downstream antioxidant expression. AKT: Protein kinase B; AP-1: Activator protein 1; ASK1: Apoptosis signal-regulating kinase 1; DUSP1: Dual specificity protein phosphatase 1; Egr-1: Early growth response protein 1; ERK: Extracellular signal-regulated protein kinase; FOXO: Forkhead box protein O; IAP: Inhibitor of apoptosis; IFN: Interferon; IL: Interleukin; IRAK: Interleukin-1 receptor-associated kinase 1; JNK: C-Jun N-terminal kinase; LPS: Lipopolysaccharide; MEKK1: Mitogen-activated protein kinase kinase kinase 1; MyD88: Myeloid differentiation primary response 88; NF-κB: Nuclear factor κB; NIK: Nuclear factor κB inducing kinase; NOX: NADPH oxidase; MnSOD: Manganese-dependent superoxide dismutase; PI3K: Phosphoinositide 3-kinase; PTEN: Phosphatase and tensin homolog; Rac1: Ras-related C3 botulinum toxin substrate 1; ROS: Reactive oxygen species; TAK1: Transforming growth factor beta-activated kinase 1; TLR4: Toll-like receptor 4; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; TRADD: Tumour necrosis factor alpha receptor 1-associated death domain protein; TRAF: Tumor necrosis factor receptor-associated factor; TRIF: TIR-domain-containing adapter-inducing interferon-β; TRX: Thioredoxin; TXNIP: Thioredoxin-interacting protein.

地图上有字

描述已自动生成

**Figure 4 Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation and downstream signaling.** Reactive oxygen species (ROS) activate thioredoxin-interacting protein *via* inhibition of oxidoreductase thioredoxin. Thioredoxin-interacting protein both binds and activates nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasomes and interacts with thioredoxin 1 and 2 to indirectly promote further ROS generation through inhibiting their antioxidant activity. Activated nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasomes facilitate pro-caspase 1 cleavage to caspase 1, which facilitates pro- interleukin (IL)-1β and pro-IL-18 cleavage to IL-1β and IL-18 respectively. IL-18 induces interferon-γ production by natural killer T-cells. IL-1β induces generation of T-helper 17 cells in addition to nuclear factor κB and activator protein 1 activation through IKKβ, p38, c-Jun N-terminal kinase and mitogen-activated protein kinase kinase kinase 1 stimulation. Activating nuclear factor κB and activator protein 1 results in pro-inflammatory cytokine release, indirectly inducing further ROS accumulation. AP-1: Activator protein 1; IFN: Interferon; IL: Interleukin; JNK: C-Jun N-terminal kinase; MEKK1: Mitogen-activated protein kinase kinase kinase 1; NF-*κ*B: Nuclear factor κB; NKT: Natural killer T-cell; NLRP3: Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3; NOX: NADPH oxidase; Rac1: Ras-related C3 botulinum toxin substrate 1; ROS: Reactive oxygen species; Th17: T-helper 17 cells; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; TRX: Thioredoxin; TXNIP: Thioredoxin-interacting protein.

**地图上有字

描述已自动生成**

**Figure 5 Reactive oxygen species-mediated oxidative damage in the liver.** Increased cytochrome p450 2E1-mediated alcohol breakdown and electron transport chain reduction results in overproduction of reactive oxygen species (ROS). Excess alcohol causes gut hyperpermeability resulting in tight junction disruption and an excess of lipopolysaccharide translocation from the gut to the liver. Lipopolysaccharide activates NADPH oxidase *via* toll-like receptor 4 activation resulting in further ROS production. Excess ROS produce RNS and reduce antioxidant cofactors such as Mn and Zn. ROS induce hepatocyte damage through activation of apoptosis signal-regulating kinase 1. Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasomes are activated by ROS, inducing T-helper 17 generation and natural killer T cell-mediated interferon-γ production through interleukin expression. ROS upregulate transcription factors activator protein 1 and nuclear factor κB resulting in pro-inflammatory cytokine expression causing downstream liver inflammation. Tumour necrosis factor alpha further upregulates ROS through activating NADPH oxidase *via* tumour necrosis factor alpha receptor 1. ROS cause an array of functional and structural mitochondrial damage, which is initially impeded by uncoupling proteins and SAMe expression. ROS mediates epigenetic alterations through interacting with HDACs which mediate histone acetylation. Ac: Acetylation; ADH: Alcohol dehydrogenase; AP-1: Activator protein 1; ASK1: Apoptosis signal-regulating kinase 1; Cu: Copper; CYP2E1: Cytochrome p450 2E1; ETC: Electron transport chain; HDAC: Histone deacetylases; IFN: Interferon; IL: Interleukin; LPS: Lipopolysaccharide; Mn: Manganese; NF-κB: Nuclear factor κB; NKT: Natural killer T-cell; NOX: NADPH oxidase; ROS: Reactive oxygen species; SAMe: *S*-adenosylmethionine; Se: Selenium; Th17: T-helper 17 cells; TLR4: Toll-like receptor 4; TNF-α: Tumour necrosis factor alpha; TNFR1: Tumour necrosis factor alpha receptor 1; UCP: Uncoupling protein; Zn: Zinc.